_256_384.jpg)
News | February 26, 2021
Bayer delivers robust performance despite pandemic
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.
DHL and other logistics companies were already transporting pharmaceutical products at minus 70°C in Schaumaplast boxes packed with dry ice before the coronavirus pandemic
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
The jump in profit is due to the better performance of the API business.
Be One is a 100% Ayurvedic health and wellness supplement.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
